Research ArticleExperimental Studies
Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer
KLAUDIA HOLECKOVA, KATARINA BALUCHOVA, MARK HIVES, LUDOVIT MUSAK, JAN KLIMENT and MARIA SKERENOVA
In Vivo July 2020, 34 (4) 1773-1778; DOI: https://doi.org/10.21873/invivo.11971
KLAUDIA HOLECKOVA
1Department of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovak Republic
2Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
KATARINA BALUCHOVA
3OncoLab Diagnostics, Technologie- und Forschungszentrum, Vienna, Austria
MARK HIVES
4Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
LUDOVIT MUSAK
2Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
JAN KLIMENT SR.
1Department of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovak Republic
MARIA SKERENOVA
2Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
5Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovak Republic
In this issue
In Vivo
Vol. 34, Issue 4
July-August 2020
Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer
KLAUDIA HOLECKOVA, KATARINA BALUCHOVA, MARK HIVES, LUDOVIT MUSAK, JAN KLIMENT, MARIA SKERENOVA
In Vivo Jul 2020, 34 (4) 1773-1778; DOI: 10.21873/invivo.11971
Jump to section
Related Articles
- No related articles found.
Cited By...
- An MGMT Allelic Variant Can Affect Biochemical Relapse in Prostate Cancer Patients
- Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
- Pathological Roles of Prostaglandin E2-specific E-type Prostanoid Receptors in Hormone-sensitive and Castration-resistant Prostate Cancer